Trevena's biased ligand approach has the potential to address the limited efficacy and undesirable adverse effects of many currently marketed GPCR drugs across a wide range of receptors and therapeutic areas. The company's pipeline is focused on medicines targeting pain management, including TRV734 for moderate to severe pain, TRV250 for migraines, and TRV027 for acute heart failure. Its leading product is oliceridine (TRV130), a protein-based chemical meant to manage moderate to severe acute pain. Trevena is a biopharmaceutical company focused on developing and commercializing novel medicines for patients with central nervous system (CNS) disorders.